Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
Investing.com - Macquarie downgraded Dr. Reddy’s Laboratories (DRRD:IN) (NYSE:RDY), a $12.46 billion pharmaceutical company with "GREAT" financial health according to InvestingPro analysis, from Outperform to Neutral and lowered its price target to INR1,190.00 from INR1,450.00 on Tuesday.
The research firm cited concerns that market analysts are underestimating the contribution of gRevlimid to the pharmaceutical company’s financial performance.
Macquarie reduced its FY27 earnings estimates for Dr. Reddy’s by 9% and lowered its target multiple to 25x price-to-earnings ratio.
Despite the downgrade, Macquarie maintained a positive outlook on Dr. Reddy’s new growth drivers, including over-the-counter medications, nutraceuticals, and innovative medicines.
The firm noted these new growth segments would likely scale up only gradually, contributing to the more cautious rating on the Indian pharmaceutical company.
In other recent news, Dr. Reddy’s Laboratories has entered into a collaboration and license agreement with Alvotech to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda, a leading cancer treatment. This partnership aims to leverage both companies’ strengths in the growing biosimilar market. HSBC analysts have upgraded Dr. Reddy’s stock rating to Buy from Hold, citing positive market dynamics and future earnings potential, particularly with the anticipated launch of semaglutide in several countries by early fiscal year 2027. However, JPMorgan has revised its price target for Dr. Reddy’s, lowering it to INR1,060 while maintaining an Underweight rating. This adjustment follows the company’s recent earnings report, which showed revenues meeting expectations but a shortfall in EBITDA due to decreased gross margins. The decline in margins was primarily attributed to pricing pressures in the U.S. market, especially for the drug gRevlimid. JPMorgan also noted challenges such as limited visibility on niche product launches in the U.S. and competitive pressures in the semaglutide market. Despite these challenges, the collaboration with Alvotech is expected to enhance Dr. Reddy’s presence in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.